Procept outlines 2026 U.S. procedures of 54,000 to 56,000 while targeting positive adjusted EBITDA in Q4 2026 (NASDAQ:PRCT)
· seekingalpha.com
PROCEPT BioRobotics (PRCT) Q2 2026 earnings call: revenue, HYDROS upgrades, softer procedures, and updated guidance.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...